AllianceBernstein’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.22M Sell
105,937
-46,239
-30% -$3.34M ﹤0.01% 1340
2026
Q1
$11.6M Buy
152,176
+57,868
+61% +$4.1M ﹤0.01% 1135
2025
Q4
$7.16M Buy
94,308
+2,291
+2% +$166K ﹤0.01% 1379
2025
Q3
$5.65M Buy
92,017
+47
+0.1% +$2.45K ﹤0.01% 1456
2025
Q2
$4.49M Sell
91,970
-41,313
-31% -$1.96M ﹤0.01% 1524
2025
Q1
$6.79M Sell
133,283
-228,361
-63% -$11.4M ﹤0.01% 1331
2024
Q4
$16.3M Buy
361,644
+139,596
+63% +$5.97M 0.01% 974
2024
Q3
$8.24M Buy
222,048
+126,398
+132% +$4.23M ﹤0.01% 1289
2024
Q2
$2.92M Sell
95,650
-264,507
-73% -$8.57M ﹤0.01% 1746
2024
Q1
$10.5M Buy
360,157
+6,606
+2% +$185K ﹤0.01% 1138
2023
Q4
$9.74M Buy
353,551
+222,483
+170% +$5.09M ﹤0.01% 1169
2023
Q3
$2.94M Sell
131,068
-4,129
-3% -$154K ﹤0.01% 1680
2023
Q2
$5.5M Sell
135,197
-189,703
-58% -$9.28M ﹤0.01% 1394
2023
Q1
$15.7M Sell
324,900
-23,524
-7% -$1.08M 0.01% 924
2022
Q4
$13.3M Buy
348,424
+223,554
+179% +$9.29M 0.01% 962
2022
Q3
$6.27M Buy
124,870
+32,320
+35% +$1.58M ﹤0.01% 1302
2022
Q2
$3.71M Hold
92,550
﹤0.01% 1596
2022
Q1
$3.45M Buy
92,550
+200
+0.2% +$7.71K ﹤0.01% 1771
2021
Q4
$3.68M Hold
92,350
﹤0.01% 1787
2021
Q3
$3.44M Sell
92,350
-600
-0.6% -$24.6K ﹤0.01% 1816
2021
Q2
$3.93M Sell
92,950
-1,623,987
-95% -$69.6M ﹤0.01% 1767
2021
Q1
$81.3M Sell
1,716,937
-56,430
-3% -$3.35M 0.04% 466
2020
Q4
$108M Buy
1,773,367
+34,709
+2% +$2.05M 0.05% 359
2020
Q3
$81.3M Buy
1,738,658
+74,858
+4% +$3.69M 0.04% 387
2020
Q2
$84.4M Buy
1,663,800
+62,913
+4% +$3.09M 0.05% 362
2020
Q1
$71.4M Buy
1,600,887
+1,519,037
+1,856% +$76.5M 0.05% 345
2019
Q4
$3.93M Buy
81,850
+2,800
+4% +$119K ﹤0.01% 1577
2019
Q3
$2.67M Buy
79,050
+1,100
+1% +$47.9K ﹤0.01% 1750
2019
Q2
$3.51M Buy
77,950
+19,800
+34% +$782K ﹤0.01% 1639
2019
Q1
$2.19M Sell
58,150
-53,800
-48% -$1.81M ﹤0.01% 1840
2018
Q4
$3.84M Buy
111,950
+41,600
+59% +$1.5M ﹤0.01% 1442
2018
Q3
$3.31M Hold
70,350
﹤0.01% 1577
2018
Q2
$2.37M Buy
70,350
+21,000
+43% +$655K ﹤0.01% 1795
2018
Q1
$1.33M Hold
49,350
﹤0.01% 2096
2017
Q4
$823K Hold
49,350
﹤0.01% 2375
2017
Q3
$987K Hold
49,350
﹤0.01% 2286
2017
Q2
$905K Sell
49,350
-13,200
-21% -$178K ﹤0.01% 2338
2017
Q1
$615K Sell
62,550
-7,100
-10% -$85.9K ﹤0.01% 2464
2016
Q4
$760K Hold
69,650
﹤0.01% 2396
2016
Q3
$976K Sell
69,650
-6,000
-8% -$48.8K ﹤0.01% 2235
2016
Q2
$531K Buy
75,650
+22,900
+43% +$168K ﹤0.01% 2501
2016
Q1
$340K Sell
52,750
-1,232,735
-96% -$21.4M ﹤0.01% 2545
2015
Q4
$41.6M Buy
1,285,485
+254,361
+25% +$7.49M 0.04% 492
2015
Q3
$27.5M Buy
1,031,124
+248,282
+32% +$10.6M 0.02% 590
2015
Q2
$37.7M Buy
782,842
+569,832
+268% +$33.2M 0.03% 541
2015
Q1
$13M Buy
213,010
+179,610
+538% +$11M 0.01% 846
2014
Q4
$1.73M Buy
33,400
+2,400
+8% +$106K ﹤0.01% 1848
2014
Q3
$1.36M Hold
31,000
﹤0.01% 1999
2014
Q2
$810K Buy
31,000
+30,888
+27,579% +$661K ﹤0.01% 2353
2014
Q1
$3K Hold
112
﹤0.01% 3378
2013
Q4
$2K Hold
112
﹤0.01% 3245
2013
Q3
$2K Buy
+112
New +$1.95K ﹤0.01% 3255

Other funds holding PTCT

AllianceBernstein's PTCT Position: Q2 2026 in Review

AllianceBernstein reduced its PTC Therapeutics (PTCT) stake by 30% in Q2 2026, selling an estimated $3.34M and leaving 105,937 shares worth $7.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1340.

AllianceBernstein first reported a position in PTCT in Q3 2013 and has held it in 52 quarters since. The position peaked at $108M in Q4 2020. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • AllianceBernstein held 105,937 shares of PTC Therapeutics worth $7.22M as of Q2 2026.
  • AllianceBernstein sold 46,239 PTC Therapeutics shares in Q2 2026, an estimated $3.34M.
  • PTC Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1340 holding.
  • AllianceBernstein first reported a position in PTC Therapeutics in Q3 2013 and has held it in 52 quarters since.
  • AllianceBernstein's PTC Therapeutics position peaked at $108M in Q4 2020.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.